On September 1, 2020 NeuClone Pharmaceuticals Ltd (NeuClone), a clinical-stage biopharmaceutical company developing high-quality biosimilar products, reported two additional biosimilars in active development (Press release, NeuClone Pharmaceuticals, SEP 1, 2020, View Source [SID1234564250]). The products are biosimilar candidates referencing Opdivo (nivolumab) and Keytruda (pembrolizumab
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
These biosimilars reference two antibody products that block the PD-1 immune checkpoint inhibitor pathway and their use has dramatically improved the prognosis of patients across multiple oncology settings. Combined global sales of the two reference products in 2019 were US$19.2 billion and are forecast to reach over US$32 billion in 2024.1
"These two medicines have helped reshape previous standard-of-care approaches for many cancer patients" stated Dr Noelle Sunstrom, CEO and Founder of NeuClone. "Providing affordable biosimilar alternatives is crucial to allow many more patients around the world access to these life changing treatments."
The biosimilar candidates are in the advanced stages of pre-clinical development and are being co-developed by NeuClone and its strategic manufacturing partner, Serum Institute of India (Serum Institute).
"Serum Institute is committed to co-developing a broad range of biosimilars with NeuClone to expand global market access of these valuable medicines to under-served cancer patients" stated Mr Adar Poonawalla, CEO of Serum Institute.
The disclosure of these biosimilars demonstrates NeuClone’s unique ability to develop multiple biosimilars simultaneously through its proven NeuMAX platform. In addition to these two products, NeuClone and Serum Institute are developing eight other biosimilars, including clinical-stage candidates referencing Stelara (ustekinumab) and Herceptin (trastuzumab).